STOCK TITAN

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Belite Bio, Inc (NASDAQ: BLTE) will host a webcast on November 14, 2023, to discuss financial results for Q3 2023 and provide a general business update.
Positive
  • None.
Negative
  • None.

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2023, and provide a general business update.

Webcast Information
Date: Tuesday, November 14, 2023
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://wsw.com/webcast/cc/blte/1366794

Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-elated macular degeneration, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com


Belite Bio, Inc will host the webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time.

You can join the live webcast by visiting the provided webcast link or the 'Presentations & Events' section of the Company’s Investor Relations website.

A replay will be available for approximately 90 days after the event.
Belite Bio, Inc American Depositary Shares

NASDAQ:BLTE

BLTE Rankings

BLTE Latest News

BLTE Stock Data

1.22B
11.21M
60.29%
0.81%
0.13%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
San Diego

About BLTE

belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.